Xenon and Acadia Pharmaceuticals to Present Key Clinical Data at 2026 AAN Meeting

Major biotechnology firms are preparing to showcase pivotal clinical results at the 2026 American Academy of Neurology (AAN) Annual Meeting, scheduled for April 18–22 in Chicago. Xenon Pharmaceuticals announced it will present Phase 3 results from its X-TOLE2 study for azetukalner, featuring critical 48-month long-term efficacy and safety data. Joining the lineup, Acadia Pharmaceuticals revealed it will present multiple original data sets, including real-world evidence from the Phase 4 LOTUS study evaluating DAYBUE (trofinetide) in adults. These presentations represent significant strategic milestones for both companies as they advance treatments for complex neurological disorders. Investors are closely monitoring these developments, as the data is expected to influence regulatory trajectories and future commercial prospects. The upcoming AAN meeting underscores a broader industry commitment to providing robust, long-term clinical evidence for innovative therapies.